login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Pulsar Stent shows positive outcomes in 4EVER clinical study


Wednesday, 23 May 2012 12:34
Pulsar
Pulsar

The six-month results from the prospective, multicentre, single-arm 4EVER study (Trial investigating the safety of 4F endovascular treatment of infra-inguinal arterial stenotic disease) demonstrate efficacy and safety of the Pulsar Stent System (Biotronik) in 120 superficial femoral arterypatients.


Analysis of the 120 patients showed excellent device performance, very promising patency rates and convincing evidence of the benefits of lower limb intervention on a 4F platform. Although only the interim results were presented at the Leipzig Interventional Course (LINC 2012) in Leipzig, Germany, Biotronik announced that analysis of the full cohort has recently been made available.

The 4EVER study was initiated by Marc Bosiers, Dendermonde, Belgium, to investigate the efficacy of Pulsar stents and also the feasibility of treating patients with Biotronik’s 4F devices namely the Fortress 4F sheath, together with the Astron Pulsar and Pulsar-18 SE stents.

In total, 120 patients were recruited into the study. Six-month primary patency is documented as being as high as 90.0%. Average lesion length in the Pulsar-18 subgroup was 10.5cm. On the 4F intervention side, Bosiers presented a complication rate of only 3.3% and a mean manual compression time of around 8 minutes, halving the time experienced when using 6F.


Technical success of 100% clearly supports the possibility for minimally invasive peripheral intervention of the lower limb. When asked during the Biotronik symposium at LINC 2012 whether all patients can be treated with 4F, Koen Deloose, Dendermonde, Belgium, responded, “4F is sufficient for the majority of endovascular treatments.”

Pulsar-18 stents provide an innovative design of ultrathin nitinol struts coated with Probio, a silicone carbide layer that improves the stent’s haemocompatibility and biocompatibility, which is believed to contribute to its positive clinical results. Pulsar-18 is available in diameters of 4–7mm and 20–200mm lengths deliverable through a 4F sheath.


The primary endpoint data, primary patency at twelve months, is expected to be presented at CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 15–19 September 2012 in Lisbon, Portugal.




Add New Comment

Related Items


Most popular


DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients
Friday, 29 Aug 2014
The multicentre, 800-patient study also demonstrated that directional atherectomy was non-inferior for treating peripheral arterial disease in patients with diabetes compared with those without ... DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients

Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak
Wednesday, 13 Aug 2014
Elective open surgical conversion for type Ia endoleak after endovascular aneurysm repair (EVAR) is not associated with increased morbidity or mortality compared with open juxtarenal aneurysm repair ... Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak

High patency rates with early cannulation graft with bioactive surface
Friday, 15 Aug 2014
Results of vascular access using a new ePTFE graft show “satisfactory” primary patency rates at one year, and are similar to those achieved with an autogenous access. In the experience, conducted in ... High patency rates with early cannulation graft with bioactive surface

Features


Eversion carotid endarterectomy: A technique that matters
Wednesday, 10 Sep 2014
Philip S K Paty, Albany, USA, says that eversion carotid endarterectomy is the preferred technique to treat carotid artery disease. Over the past two decades, his centre has performed over 11,000 of ... Eversion carotid endarterectomy: A technique that matters

SPECT can predict cardiovascular mortality in elective aneurysm repair patients
Wednesday, 12 Mar 2014
Kimihiro Komori and Yosuke Inoue analyse the results of a study that concluded that preoperative pharmacologic stress myocardial perfusion SPECT is not only safe, but is also a useful method to ... SPECT can predict cardiovascular mortality in elective aneurysm repair patients

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions